Abbott Laboratories: A Vascular Sales Pitch and a Defense Verdict

Whistleblower Justice Network

The Abbott False Claims Act case over biliary stents ended in a defense verdict after a former territory manager alleged that the company promoted bile-duct medical devices for vascular procedures and helped providers bill Medicare for them. His account reached inside the sales operation: the disclaimer before the pitch, the anatomy used in training, the quotas and the reimbursement guides. The case turned on how those activities connected to government claims.

The whistleblower had sold stents for Guidant, whose stent business Abbott acquired. He brought a qui tam case, and the government declined to join. The court’s account of the case traces separate paths for the claims about Food and Drug Administration clearance, kickbacks and Medicare billing. Each reached a different part of the business, from the product’s intended use to the provider’s request for payment.

Bile-Duct Labels, Vascular Sales

The alleged commercial strategy was to sell medical devices cleared for the bile ducts into the larger vascular market. The district court’s account of the amended complaint describes biliary stents as medical devices used to keep bile ducts open in patients with cancer. Vascular stents support blood vessels. The whistleblower alleged that the manufacturers sought clearance by comparing their products with existing biliary medical devices, avoiding the more demanding premarket approval process and clinical studies for vascular use.

According to the original complaint, the territory manager called on interventional cardiologists, interventional radiologists and vascular surgeons. Of those specialties, the complaint said, only interventional radiologists were trained to place stents in the bile ducts. He alleged that he attended live procedures and supplied technical support, yet never saw the biliary medical devices used in the bile ducts.

The original complaint described a sales script that acknowledged the label before moving past it:

Similarly, sales reps are trained to preface any conversation with a physician about the use of stents in the peripheral vascular system with a “canned comment” that the stents are not indicated for “peripheral vascular system use.”

Whistleblower’s allegation, United States ex rel. Colquitt v. Abbott Laboratories, original complaint, paragraph 24

The warning that the stents were not meant for blood vessels was, according to the complaint, how the vascular sales pitch opened. The training described in the amended complaint pointed in the same direction: representatives practiced deploying biliary stents in models of vascular anatomy. The models had no biliary anatomy, and the training supplied no laboratory instruction on placing stents in the bile ducts.

The original complaint made the compensation incentive equally direct:

Relator’s quota and compensation was predicated on the fact that he would market off-label the biliary stents for non-indicated uses.

Whistleblower’s allegation, United States ex rel. Colquitt v. Abbott Laboratories, original complaint, paragraph 32

The amended complaint added that the territory manager identified cardiologists and vascular surgeons likely to use large numbers of stents and helped direct them into company-sponsored training. It also described a practice-building program with physician letters, patient questionnaires and advisory letters for vascular specialists to send to their patients. The alleged sales effort reached from finding the customer to developing the customer’s practice.

How Does Reimbursement Work for Medical Devices?

In this case, the amended complaint alleged that manufacturers stocked biliary stents in departments performing vascular procedures and charged the hospital when a stent was used. It also alleged that Abbott tracked the consigned medical devices to measure physicians’ off-label use and its vascular market share.

The alleged effort continued into billing. The district court described Abbott reimbursement guides that instructed health care providers to use vascular-procedure codes for procedures involving its stents. One guide addressed outpatient and physician coding for coronary and peripheral vascular procedures. The whistleblower alleged that those instructions helped turn the promoted use into claims to Medicare and Medicaid.

That is the commercial connection the case put under scrutiny: a representative promoted a use, the hospital supplied the medical device, and the provider sought government payment. The complaint alleged that reimbursement sustained the market the manufacturers were pursuing. The billing guide sat alongside the sales pitch because payment helped make the sale possible.

The False Claims Act Allegations Reached Across the Business

The case challenged statements to the Food and Drug Administration, financial inducements to providers and claims submitted to Medicare.

The Product’s Intended Use

The whistleblower alleged that the manufacturers misrepresented the stents’ intended use to obtain biliary clearance from the Food and Drug Administration. The district court’s account of the amended complaint described his allegation that 99% of the manufacturers’ medical devices were too large or too small for the bile ducts, or came mounted on delivery catheters of the wrong size.

The court’s later opinion gave a concrete example from the complaint: Guidant’s stents came with a 75 centimeter catheter, while biliary catheters should be less than 50 centimeters or greater than 170 centimeters. The whistleblower alleged that the dimensions and production volumes pointed to medical devices intended for the vascular market.

Kickbacks

The kickback theory alleged that rebates and other benefits induced providers to choose the stents, followed by reimbursement claims falsely certifying compliance with the Anti-Kickback Statute. The amended complaint described Abbott hospital rebates tied to market share and dinners intended to encourage referrals to vascular specialists using its products.

The court found that the complaint did not connect those benefits to hospitals’ purchase and use of Abbott stents. It lacked specifics about the rebate thresholds, whether hospitals reached them through vascular use, and which doctors’ benefits led to purchases. A rebate plan, the hospital’s purchasing results and the physician’s product decisions tell different parts of that story.

Promotion and Medicare Claims

The district court allowed the claim about Abbott’s promotion causing false Medicare bills to go forward. Its account tied the reimbursement guides to the promotional activities: the guides described how providers should seek payment for the vascular procedures being promoted.

The Payment Dispute at Trial

Abbott’s defense emphasized that vascular use of biliary stents was standard practice, known to the government and commonly reimbursed by Medicare. The company presented testimony from physicians and a former Medicare officer. The payment question was central: the surviving claim alleged that Abbott caused bills for procedures that were ineligible for Medicare reimbursement.

The court distinguished Medicare’s payment policies from the FDA’s position on marketing. A dispute about promotion had to connect to the payer’s decision about the care being billed.

The Records Behind the Pitch and the Bill

Sales, training, inventory and billing staff see different parts of this transaction. Those records describe what representatives were expected to sell, where the medical devices went and how providers were encouraged to seek payment.

The 2020 review A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, published in the Journal of Forensic and Investigative Accounting, examines who sought payment, what they knew and how their conduct caused the claim. In this case, the sales records, purchase decisions and reimbursement guides show different sides of the same transaction.

Our whistleblower experts work with the person who can explain those connections from inside the business. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know How the Medical Device Was Sold

If you worked with the sales scripts, training programs or reimbursement guides behind a medical device sale, speak to one of our whistleblower experts about how the pitch reached the bill. We build the case with you and bring in medical device fraud whistleblower lawyers who understand manufacturer promotion and provider billing. We stay beside you as your knowledge of the business becomes the foundation of the case.

WHISTLEBLOWER JUSTICE NETWORK CAN HELP YOU
Make a difference.
Whistleblower Justice NetworkReport Fraud
100% CONFIDENTIALFREE CONSULTATION24 / 7 / 365